Toxicogenomics has great potential for enhancing our understanding of environmental chemical toxicity, hopefully leading to better informed human health risk assessments. This study employed toxicogenomic technology to reveal species differences in response to two prototypical aryl hydrocarbon receptor (AHR) agonists 2,3,7,8-tetrachlorodibenzo-p-dioxin and the polychlorinated biphenyl (PCB) congener PCB 126. Doseresponses of primary cultures of rat and human hepatocytes were determined using species-specific microarrays sharing over 4000 gene orthologs. Forty-seven human and 79 rat genes satisfied dose-response criteria for both chemicals and were subjected to further analysis including the calculation of the 50% effective concentration and the relative potency (REP) of PCB 126 for each gene. Only five responsive orthologous genes were shared between the two species; yet, the geometric mean of the REPs for all rat and human modeled responsive genes were 0.06 (95% confidence interval [CI]; 0.03-0.1) and 0.002 (95% CI; 0.001-0.005), respectively, suggesting broad species differences in the initial events that follow AHR activation but precede toxicity. This indicates that there are species differences in both the specific genes that responded and the agonist potency and REP for those genes. This observed insensitivity of human cells to PCB 126 is consistent with more traditional measurements of AHR activation (i.e., cytochrome P450 1A1 enzyme activity) and suggests that the species difference in PCB 126 sensitivity is likely due to certain aspects of AHR function. That a species divergence also exists in this expanded AHR-regulated gene repertoire is a novel finding and should help when extrapolating animal data to humans.
Modern biotechnologies (e.g., toxicogenomics) are rapidly evolving and show great promise in improving our understanding of the biological mechanisms underlying toxic responses to pharmaceuticals and environmental chemicals (National Research Council [NRC], 2007a) . In addition, recent reports have endorsed the development of in vitro approaches for modern toxicity testing (EPA, 2009; NRC, 2007b) . In fact, they highlight the need to develop better dose-response data and improved models for extrapolation across species. As described by NRC (2007b) , such extrapolation modeling will have at least three components: (1) a mechanistic understanding of dose-response modeling; (2) pharmacokinetic modeling that can relate effects seen at certain in vitro concentrations to effective concentrations in human tissue; and (3) human data regarding elements of the same toxicity pathway. This approach certainly has the potential to improve the accuracy of modern human health risk assessment.
Current human health risk assessment approaches have a high reliance on responses observed in laboratory animals from both in vitro and in vivo models. While responses of animals and animal cells to some toxicants have been shown to be generally predictive of human health risk (e.g., certain heavy metals, alkylating agents, and polycyclic aromatic hydrocarbons), simple interspecies extrapolations are not always valid. This is particularly evident for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and structurally related dioxin-like compounds (DLCs) . Although the cellular responses to TCDD are initiated through a well-researched receptor-based mechanism, the aryl hydrocarbon receptor (AHR) pathway (reviewed by Okey, 2007) , it is also well established that the potency of TCDD is not consistent across species (Henck et al., 1981; Schwetz et al., 1973) . To date, some species/strain differences in TCDD potency have been attributed to variation in AHR gene sequence leading to differential ligand-receptor affinity. For example, divergent TCDD toxic potencies seen between responsive C57 and nonresponsive DBA mice strains are generally due to an amino acid substitution in the AHR ligand-binding domain resulting in differential AHR affinity for TCDD between these strains (Ema et al., 1994; Okey et al., 1989; Poland et al., 1994) . Interestingly, the human AHR has the very same affinitylowering amino acid substitution as the DBA mouse leading to reduced TCDD potency for cytochrome P450 1A1 (CYP1A1) enzyme induction in vitro (Ema et al., 1994; Harper et al., 1988; Ramadoss and Perdew, 2004 ) and a much milder/incomplete TCDD toxicity in transgenic mice ''humanized'' with the human AHR Moriguchi et al., 2003) .
It is also increasingly evident that DLCs may not retain their relative potencies (REPs), as compared to the potency of TCDD, across species. Species variation in REPs may be due to a number of reasons including species differences in toxicokinetics. However, species differences in explicit AHR pharmacology (e.g., affinity and/or intrinsic efficacy) may also lead to deviating REPs. For instance, estimated REPs for mono-ortho-substituted polychlorinated biphenyls (PCBs) differ greatly between fish and rodents ( Van den Berg et al., 1998) . Using an in vitro system, Hestermann et al. (2000a) determined that the general inability of mono-ortho PCBs to elicit embryotoxicity and induce CYP1A in various fish species is due to the exceptionally low intrinsic efficacy of these congeners to activate the AHR in fish cells.
In vitro studies using primary cells and cell lines suggest that species differences exist between humans and rodents in the REP of PCB 126 for CYP1A1 enzyme induction (Drenth et al., 1998; Pang et al., 1999; Silkworth et al., 2005; Vamvakas et al., 1996; van Duursen et al., 2003; van Duursen et al., 2005; Westerink et al., 2008; Zeiger et al., 2001) . In addition to the lesser potency of TCDD, the REP of PCB 126 in human cell systems appears to be almost two orders of magnitude lower than numerous findings in rodents and rodent cell cultures (Haws et al., 2006) . This species discrepancy is toxicologically significant because PCB 126 is a persistent coplanar PCB, the most potent PCB AHR agonist in rodents (i.e., REP PCB126 is one-tenth that of TCDD), and displays a relatively high affinity for AHRs of ''responsive'' rodents (e.g., C57 mice and SpragueDawley rats) (Bandiera et al., 1982; Safe et al., 1985) . In addition, the apparent difference in in vitro PCB 126 REP estimates between human and rodent is not likely due to species differences in the affinity of the AHR for PCB 126. Specifically, PCB 126 maintains a ''relative affinity'' (compared to TCDD) of approximately 0.02 for both human and responsive rat AHR proteins (Fan et al., 2009) . Furthermore, the human AHR, when expressed in the liver of transgenic humanized C57 mice, also exhibits, as seen with TCDD, the expected 10-fold lesser binding affinity for PCB 126 compared to responsive wild-type C57 mice ). This 10-fold lesser affinity of PCB 126 can also be easily explained by the human AHR having the same ligand-binding domain amino acid substitution as ''nonresponsive'' DBA mice. However, this does not explain the apparent and even exaggerated response insensitivity of human cells to PCB 126. Thus, the remarkable species difference in PCB 126 REP might be due to species differences in relative intrinsic efficacy (compared to TCDD) rather than species differences in relative AHR affinity.
It is evident that the AHR is responsible for the suite of toxicities observed in rodents exposed to TCDD and DLCs (Okey, 2007; Perdew, 2008) . However, the prototypical AHRregulated gene, CYP1A1, appears not to play a prominent role in some TCDD toxicities (Nukaya et al., 2009; Pohjanvirta, 2009; Uno et al., 2004) , questioning its use as a universal ''biomarker of effect.'' Since potencies and REPs of ligands may vary across responses mediated by the same receptor in the same cell type, termed ''functional selectivity'' (Kenakin, 2007; Michel and Alewijnse, 2007; Urban et al., 2007) , it is important to investigate and estimate the REPs of DLCs for altering AHR-regulated genes other than CYP1A1. Studies demonstrating human-rodent differences in the REP of PCB 126 in vitro have been limited to analysis of the dose-response for CYP1A1 enzyme induction and activity. Therefore, the current investigation sought to determine if the discrepancy in REP for PCB 126 observed between rat and human cell cultures for CYP1A1 induction was also true for additional AHR-regulated genes that may play more important roles in subsequent toxicity. Genome-wide dose-responses were determined for TCDD and PCB 126 in cultures of primary hepatocytes from human and rat donors using species-specific microarrays. Species-specific TCDD 50% effective concentrations (EC50s) and PCB 126 REPs were simultaneously calculated for all genes satisfying a nonlinear mixed-effects dose-response model. By characterizing how REPs between TCDD and PCB 126 vary among the responsive genes and across species, one should gain greater insight into the human toxicological response to AHR activation. Overall, this study is consistent with the vision outlined in the recent NRC report (NRC, 2007b) to develop a greater understanding of how to use in vitro-derived data to predict toxicity across species.
MATERIALS AND METHODS
Chemicals. TCDD (molecular weight ¼ 322) was obtained from Accustandard (New Haven, CT; catalog no. D404N; chemical abstract service (CAS) no. 1746-01-6; Lot no. 970401R-AC; 99.1% pure). The single contaminant was a pentachlorohydroxydiphenyl ether by gas chromatography/mass spectrometry (GC/MS). PCB 126 (molecular weight ¼ 326.4) was obtained from Accustandard (catalog no. C-126N; CAS no. 57465-28-8; Lot no. 081699MT-AC; 99.2% pure). The single contaminant was identified as a tetrachlorobiphenyl by GC/MS.
Hepatocyte Sources. Cultures of human hepatocytes were prepared from nontransplantable human tissue acquired after informed consent for use in research by In Vitro Technologies, Inc. (IVT; Baltimore, MD). An external Food and Drug Administration-certified Institutional Review Board approved the use of human tissue for ADME-Tox research at IVT. Human donor 1 (WRG), IVT Lot MHU-L-052004, was a 41-year-old Caucasian male who died from an astrocytoma. Human donor 2 (RFA), IVT Lot FHU-L-072004, was a 56-year-old Caucasian female who died from a cerebrovascular accident. Human donor 3 (ZYZ), IVT Lot MHU-L-0730044, was a 46-year-old African-American male who died from anoxia. Donors 1, 2, and 3 of the current study correspond to human donors 3, 4, and 5 from the study of Silkworth et al. (2005) , respectively. Serology for all human donors tested negative from human immunodeficiency virus, hepatitis B virus, and hepatitis C virus but positive for cytomegalovirus. Urinalyses and blood chemistries for all donors were within normal limits. Rat hepatocytes were isolated by IVT from six female Sprague-Dawley rats (Crl:CD(SD)IGS BR, Charles River Laboratories, Wilmington, MA) and divided into two pools of three rats each (i.e., termed Rat pool 1 and Rat pool 2). Rats were treated in accordance with the Animal Welfare Act.
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Hepatocyte Cultures and Chemical Treatments. Hepatocytes were isolated according to the two-step collagenase perfusion procedure of Li et al. (1992) . Isolated hepatocytes were counted using trypan blue exclusion to determine yield and to confirm >70% viability. TCDD and PCB 126 stock solutions were prepared in dimethyl sulfoxide (DMSO) as previously described (Silkworth et al., 2005) . Established 48-h cell cultures were exposed to seven concentrations each of TCDD (ranging from 10 À14 to 10 À6.5 M) or PCB 126 (10 À12 to 10 À5 M) or vehicle control (DMSO) in serum-free media for an additional 48 h at 37°C/5% CO 2 . Serum-free medium was used, since serum can significantly reduce the cellular uptake of these chemicals (Hestermann et al., 2000b) . Exposure media was changed once at 24 h post-exposure initiation. The final DMSO concentration in the incubations (including the vehicle control) was 0.5%. There were no visible indications that any chemicals had precipitated at any of the incubation concentrations, but this was not analytically confirmed. Culture viability was assessed for each exposure group as previously described (Silkworth et al., 2005) . TCDD and PCB 126 did not affect culture viability at any concentration tested.
RNA Extraction and Microarray Processing.
After 48 h treatment, total RNA was isolated from cells of each culture using TRIzol Reagent (Invitrogen Life Science, Carlsbad, CA). Cells were washed with ice-cold PBS and then disrupted by the addition of TRIzol Reagent followed by scraping. The 30 ml of cell solution was sent frozen at À70°C to the University of Memphis, where RNA isolation was completed. The solution was thawed at room temperature and let sit for 5 min. Total RNA was then isolated according the manufacturer's instructions. The RNA was dissolved in RNAse-free water and quantified by spectrophotometry. Quality of RNA isolations was determined using the Agilent BioAnalyzer 2100 (Agilent, Palo Alto, CA). Yields of rat RNA ranged from 59 to 200 lg. The RNA integrity numbers of all rat samples were 10. Yields of human RNA ranged from 56 to 153 lg. Again, RNA integrity numbers of all human samples were 10. One RNA sample from each exposure group was analyzed using Affymetrix Genechip technology according to the standard protocol. A single technical replicate (i.e., all procedures following RNA isolation were repeated on different days) was also generated for one PCB 126-exposed human cell culture. However, this technical replicate was only used for preliminary analyses and not included in the final modeling procedure. Human samples were analyzed using HG-U133A arrays (22,283 probe sets) and rat samples with RG-U34A arrays (8799 probe sets). The final data set utilized 40 human and 26 rat arrays following quality control (QC) analysis (see Probe Set Orthology Analysis subsection of Supplementary File 1 and QC results presented in Supplementary File 2). All raw microarray data (i.e., .CEL files) are available in the Gene Expression Omnibus (GEO; www.ncbi.nlm.nih. gov/geo) as series GSE14555.
Microarray Data Preprocessing. For dose-response modeling, all .CEL files (within each species) were preprocessed using the default settings of the justGCRMA function of gcrma package version 2.8.0 (Wu et al., 2004) as implemented in R version 2.4.1 (R Development Core Team, 2006) . This function background corrects perfect-match probe intensities using probe sequence information, log 2 transforms the data, quantile normalizes across the arrays, and summarizes probe intensities via the robust multiarray average method (Irizarry et al., 2003) to give an intensity value (log 2 scale) for each probe set. All gcrma-processed intensity data for each probe set are available online at (www.ncbi.nlm.nih.gov/geo) as GEO series GSE14555. Probe sets were annotated with NetAffx annotation release #25 for rat chips (RG-U34A) and release #24 for human chips (HG-U133A).
Following preprocessing, fold change estimates were produced for each probe set by first back transforming the data from log 2 and then dividing the probe set intensity for exposed cells by the vehicle control within each human donor/rat pool. Thus, if expression levels of both exposed and control were identical, then fold change equals one for that species-, chemical-, and subjectspecific dose group. Fold change estimates for all rat and human probe sets are given in Supplementary Files 3 and 4, respectively.
REP Dose-Response Modeling. Figure 1 depicts the dose-response model selection procedure. Gene expression data were run separately through this four-step selection scheme for induced and repressed probe sets (within each species) due to different constraints required for some model parameters (described below). In step 1, probe sets that did not respond in cell cultures from at least two subjects/pools were removed using a fold change filter. For human data, in order to pass the filter, a !2 absolute fold change (i.e., either twofold induced or 0.5-fold repressed) in response to TCDD was necessary for at least two out of the three human donor cultures. The same filter was applied to the rat data except that !twofold change (induced or repressed) was needed for both rat pools in order to pass the initial filter.
Preliminary analyses revealed that for many probe sets passing the initial filter in step 1 data derived from one of the human donors failed to exhibit a fold change >1.5 for any TCDD dose (i.e., a nonresponsive human donor cell culture for that particular probe set). Inclusion of such data in downstream analyses either resulted in a failure to achieve model convergence or, if a model did converge (i.e., a model fit was achieved), relatively large within-group error standard deviations and parameter estimates with extremely wide confidence intervals (CIs) (see example in Supplementary File 5). Therefore, in step 2, any nonresponsive human donor data, within a probe set, were independently eliminated from downstream analyses. This was accomplished in a nonstringent manner for each human probe set by removing all donor-specific data if that donor cell culture did not exhibit a fold change !1.5 (induced or repressed) for any dose of TCDD. Thus, for many human probe sets, data from only two human donors were used for dose-response modeling. Nonresponding probe sets from rat pools were not present in the rat data set because the initial fold change filter in step 1 ensured that both pools responded at least twofold.
A modified version of the Hill equation (Hill, 1913) was employed for doseresponse modeling in step 3 defined as
where l(d) is the estimated mean fold change response for a population at dose d (log 10 M), a the maximal agonist effect (i.e., the change in height of the right asymptote), p the potency (log 10 M) at a/2 (i.e., EC50), and g the Hill coefficient (also known as the Hillslope). The baseline expression level at d ¼ ÀN is equal to 1 for fold change data, allowing for this Hill model parameter to remain constant at 1. One goal of the current study was to accurately estimate the REP PCB126 for all dose-response probe sets. In order to achieve this goal, dose-response curves were fit simultaneously for both TCDD and PCB 126 (the REP dose-response model) using the following indicator Equation 2:
where p TCDD is the estimated EC50 for TCDD (i.e., the base chemical) and Dp is the relative change in EC50 (from TCDD) for PCB 126 data. The indicator functions I TCDD and I PCB126 are equal to 1 when calculating the response of the subscripted chemical; otherwise, they are equal to 0. Therefore, if the EC50s for both TCDD and PCB 126 were identical, then the estimated Dp would be equal to 0. Thus, the REP PCB126 can be easily derived from Dp using Equation 3.
In addition, the EC50 for PCB 126 could also be generated by adding the estimates for Dp and p TCDD together.
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In order to maintain equal maximal agonist effects and parallel doseresponse curves, which would be expected since PCB 126 is a full AHR agonist in primary hepatocytes from humans and rats (Silkworth et al., 2005) , both the maximal change in response a and Hill coefficient g were set not to vary between chemical congeners. However, preliminary analyses indicated that a and, in some instances, both a and p TCDD could vary significantly among cell cultures derived from different human donors. Thus, it was apparent that many probe sets would require a nonlinear mixed-effects model with random effects allowing either a only or both a and p TCDD to vary among cell cultures derived from different human subjects/rat pools.
Finally, four separate models (see below) were attempted during step 3 of the model selection procedure for each probe set passing the initial fold change filter.
FIG. 1.
Model selection scheme used to determine those genes (represented by probe sets) that satisfied dose-response criteria. Each probe set that passed an initial fold change filter in step 1 proceeded to step 2 where data for any nonresponsive human donor were removed.
Step 3 tested for convergence using models 1-4 (described in the Materials and Methods section). Nonlinear models 2-4 that converged were only accepted if deemed significantly (p 0.01) better fits than model 1 (i.e., intercept-only model) using LRTs. If multiple nonlinear models were deemed significantly better fits than model 1, the best-fit model was selected by nested LRTs (p 0.05) and, if necessary, lowest AIC.
Step 4 tested any nonlinear model selected during step 3 for homogeneity of residual variance using the BP test against heteroscedasticity (Breusch and Pagan, 1979) in step 4. The effects of incorporating a weighted power variance model (via LRT, lowest AIC, and BP tests) were then determined for any models demonstrating significant (p 0.05) heteroscedasticity prior to selection of the final nonlinear dose-response model. 
Model 1 represents a flat response that does not change with dose d and has a y intercept of 1 (intercept-only model). Model 2 is a generalized nonlinear least squares model (i.e., no random effects), where each parameter in Equation 1 is explained by f(), and e represents the residual error of l(d). Model 3 is a nonlinear mixed-effects model with each parameter in Equation 1 explained by f() whose arguments include a single random effect b i , which represents the variability of fixed term a among the subjects/pools i. Model 4 is identical to model 3 with the exception of an additional random effect in the arguments of f (), where b 1i and b 2i represent the variability of fixed terms a and p TCDD , respectively, among the subjects/pools i. The value of index i depended upon the number of donors/pools used in the dose-response modeling (i.e., i ¼ 1, . . .,
All random effects in models 3 and 4 are assumed to be normally distributed with mean 0 and variance-covariance matrix W (i.e., a general positive-definite matrix). The residual errors e and e i are assumed to be independently distributed as N (0,r 2 ) and e i independent of any random effects. The EC50 TCDD estimate (i.e., p TCDD ) was constrained to be between À14 log 10 M and À6.5 log 10 M to ensure a maximal TCDD response was achieved within the observed dose range. The Hill coefficient (g) was constrained to be !0. Since induced and repressed probe sets were modeled separately, a was constrained to be !1 for induced probe sets and constrained between 1 and 0 for repressed probe sets. The method for estimation of model parameter starting values is given in the Model Starting Value Estimation subsection of Supplementary File 1.
Initial model selection in step 3 was conducted by testing any nonlinear models that converged (i.e., models 2, 3, and/or 4) against the intercept-only model (model 1) by likelihood ratio tests (LRTs) at a stringent significance level of p 0.01, and the Akaike information criteria (AIC) of each model were compared (Akaike, 1974) . If any nonlinear model failed to be significantly better than model 1 (i.e., either p > 0.01 or p 0.01 and AIC model 1 < AIC of nonlinear model), it was removed from further analyses. For the second selection round, the best fitting model was determined by nested LRTs and, if LRT was significant at the p 0.05 level, the lowest AIC. The most parsimonious model (i.e., order of complexity was models 2 < 3 < 4) was chosen if any LRT failed to reach the stated significance level of p 0.05. Preliminary analyses of selected best-fit dose-response models indicated that the residual variance might not be constant with increasing/decreasing predicted response for some probe sets (e.g., the human probe set for CYP1A1). Methods for the variance modeling procedure used in step 4 are described in the Residual Variance Modeling subsection of Supplementary File 1.
Finally, for later derivation of EC50 and REP values, maximum likelihood estimates (MLEs; i.e., approximations of the population mean) and 95% upper and lower confidence bounds for parameters a, p TCDD , Dp, and g were recorded for each modeled probe set following completion of the model selection scheme depicted in Figure 1 . For graphing purposes and tabular data, Dp was converted to the REP PCB126 values using Equation 3. In addition, for summary statistics, it was necessary to remove data from redundant probe sets representing the same species-specific gene. This was always accomplished in the most conservative manner. For example, when determining the geometric mean REP, redundant probe sets were removed by only using data from the probe set with the lowest Dp MLE (i.e., the highest REP PCB126 estimate).
Various functions in the R package nlme version 3.1-88 (Pinheiro and Bates, 2004) were used for the dose modeling procedure: model 1 was fit with gls, model 2 with gnls, and models 3-4 employed the nlme function. The ''method'' argument for all models was set to ''ML'' or maximized log likelihood. The nonparametric Kruskal-Wallis rank sum and Mann-Whitney tests were performed using the kruskal.test and wilcox.test functions of the R package stats. Post hoc testing following significant (p 0.05) Kruskal-Wallis tests utilized the kruskalmc function of the pgirmess package of R.
RESULTS

Microarray Rat/Human Ortholog Analysis
The main objective of the present study was to determine if the previously observed species difference in PCB 126 REP for CYP1A1 induction/activity also applied to genes other than CYP1A1. To accomplish this, it was necessary to identify genes that demonstrated a dose-response to both TCDD and PCB 126 in either species. It was also important to identify orthologous rat/human genes that were present on the two species-specific microarrays used in this investigation. The complete methodology for this comparative examination is given in the Probe Set Orthology Analysis subsection of Supplementary File 1. Overall, somewhere between 4158 and 4190 orthologs were shared between the two microarrays. The exact number of shared orthologs could not be determined because some human Entrez gene IDs were actually orthologous to multiple rat Entrez genes. Approximately 96% of the human orthologs identified on the rat RG-U34A array were also represented on the human HG-U133A array. Conversely, approximately 39% of the rat orthologs identified on the human HG-U133A array were also present on the rat RG-U34A array. However, this microarray gene overlap, determined by an entirely automated process, was limited by the quality/ completeness of several databases and the accuracy of the microarray probe set annotation.
Preliminary Analysis of CYP1A1 Dose-Response Data
A preliminary analysis of REP dose-response curves fit by models 2-4, as well as additional models not used in the full analysis, was conducted with the HG-U133A probe set 205749_at representing the known AHR-regulated human gene CYP1A1. Visual inspection of dose-response data for CYP1A1 revealed that at least a random effect allowing the a parameter to vary among individual human donor cell cultures was needed. This was statistically validated by comparing fits for model 2 (i.e., no random effects) and model 3 (a random only) by a LRT (Table 1) . Although model 4 did converge, this more complex model was not proven a significantly (p ¼ 0.09) better fit than the more parsimonious model 3. Other models, differing in random effects from models 3 and 4 (e.g., a model with p TCDD as a random effect only), were also attempted, but these models either did not converge or were not deemed significantly better fits than model 3 as determined by nested LRTs and/or lowest AIC (data not shown).
Plotting Figure 2a depicts the donor-level doseresponse for the human CYP1A1 probe set (i.e., 205749_at) predicted by the final model chosen (i.e., model 3 extended with a power variance function) via the model selection scheme in Figure 1 . For comparative purposes, the dose-response for rat Cyp1a1 probe set E00778cds_s_at predicted by model 3 is given in Figure 2b .
The PCB 126 REP for the human CYP1A1 probe set 205749_at was 0.001 (95% CI ¼ 0.00047, 0.0022) and REPs for the rat Cyp1a1 probe sets E00778cds_s_at and E00717UTR#1_s_at were 0.068 (95% CI ¼ 0.02, 0.24) and 0.027 (95% CI ¼ 0.0049, 0.15), respectively (Supplementary File 6). Thus, as previously determined by Silkworth et al. (2005) , the present investigation has reproduced the robust species divergence in the REP of PCB 126 for induction of CYP1A1 gene expression using a different technology, microarrays. Table 2 summarizes the results from the REP dose-response model selection scheme (Fig. 1) . Altogether, 831 human probe sets and 365 rat probe sets passed the initial fold change filter in step 1. However, many probe sets were subsequently eliminated due to failure to generate any convergent doseresponse nonlinear models (i.e, model 2, model 3, or model 4) in step 3 (Fig. 1 ). Nonlinear models were selected for a total of 57 human probe sets (45 induced and 12 repressed) and 97 rat probe sets (48 induced and 49 repressed). In this report, EC50 and REP values are estimates derived from model output parameters. Such parameter MLEs used to estimate EC50 and REPs and their 95% upper and lower confidence bounds for all rat and human probe sets successfully modeled are given in Supplementary File 6. In addition, boxplots of residuals and plots of residuals versus fitted values are presented in Supplementary Files 7 and 8 for all modeled human and rat genes, respectively. Table 3 summarizes the EC50 TCDD (i.e., p TCDD ) and REP PCB126 estimates for the 10 most induced (i.e., largest a MLE) and 10 most repressed (i.e., smallest a MLE) human probe sets. For convenience, REP estimates are reported in Table 3 , rather than Dp, as calculated using Equation 3. Model estimates for the 10 most induced and 10 most repressed rat probe sets are given in Table 4 .
REP Dose-Response Modeling
One important observation was that significant variation in predicted maximal agonist effect (i.e., a parameter) existed not only among human donor cell cultures but also between cell cultures derived from the two separate rat pools. This is clearly demonstrated by the selection of models possessing at least an a random effect (i.e., models 3 and 4) for a significant number of probe sets during step 3 (Table 2 ). Such variation could be due to interindividual differences in response or to technical variation. Since fresh primary human hepatocyte cultures were used, cells from the different human donors could not be cultured, exposed, and processed for RNA isolation on the same day. For consistency, experimentation on the two rat pools was similarly conducted at different times. In addition, all procedures downstream of RNA isolation (including array hybridization) were done in batches that did not overlap among human donors or between rat pools. Therefore, potential ''batch effects'' were primarily confounded within donors/pools.
A single technical replicate was performed on a human donor 2 sample (i.e., À12 log 10 M PCB 126 dose), where all technical processes following RNA isolation were conducted at different times on the same RNA sample. This limited analysis revealed a relatively higher correlation at both the probe level and probe set level (i.e., gcrma preprocessed) between the technical replicates compared to a biological replicate or another low-dose, donor-matched array processed in the same ''batch'' (data not shown). Thus, this replicate does provide some evidence that technical differences following RNA isolation may account for a limited amount of the total variation observed in this study, but it does not rule out the potential influence of technical variation introduced prior to and including RNA isolation. Variation in cell culture response level was clearly evident among the human donors. Nonresponsive human donor data were removed for nearly 53% of the human probe sets (i.e., either induced or repressed) during step 2. Although there did not appear to be a trend as far as which human donor cell culture was identified as nonresponsive in step 2, the cell culture for human donor 2 was identified as nonresponsive for 42% of all human probe sets subsequently modeled in step 3. In addition, for many probe sets where donor 2 data were not removed in step 2, the general lower responsiveness of the cultures derived from human donor 2, similar to that seen for 
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human CYP1A1 (Fig. 2a) , appeared to be driving the selection of models possessing at least an a random effect in step 3. All modeled human probe sets where a nonresponsive donor was removed in step 2 are clearly marked in Supplementary File 6.
Removal of donor-specific data added potential bias to this study toward finding more genes displaying a dose-response to both TCDD and PCB 126. Implementation of the step 2 procedure (Fig. 1 ) resulted in the successful modeling of 20 additional human probe sets that failed to generate convergent models if step 2 was not conducted (data not shown). Furthermore, for many probe sets with a nonresponsive donor that were modeled without step 2 implementation, subsequent removal of the nonresponsive donor data resulted in lower within-group error standard deviations and parameter estimates with relatively narrower CIs (e.g., see Supplementary File 5).
Since databases are constantly being updated, probe sets were curated using Entrez gene IDs to account for redundant probe sets, update gene names, and correct the initial annotations for the chips used. Overall, 47 distinct human and 79 distinct rat genes were identified. But, in highlighting the importance of this curation, three rat probe sets (J03524_s_at, J02669_s_at, and U10697_s_at) had each been Steps 1-4 as depicted in Figure 1 . The effect of various steps in the model selection scheme. Step 2 was only conducted for human gene expression data.
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mapped to multiple genes due to a lack of probe specificity and/or poor rat gene annotation. After such correction, a total of 75 distinct rat expression measures were successfully modeled for REP and used for downstream analyses of model parameters.
Having identified a set of responsive gene probe sets for both species, we could then test the initial hypothesis that there are genes, in addition to CYP1A, for which the PCB 126 REP for human cells is also far less than 0.1 (i.e., the approximate mean value observed in mainly rodent studies as summarized by Haws et al. 2006 ). For each model, a one-tailed hypothesis test was conducted to test whether the Dp parameter was significantly greater than 1 (i.e., REP PCB126 < 0.1), and results were recorded in Supplementary File 6. For human models, 77.5% (i.e., 44 out of 57 probe sets) possessed REP estimates significantly (p 0.05) lower than 0.1. Only 17.5% of rat modeled probe sets (i.e., 17 out of 97) had REP estimates significantly (p 0.05) lower than 0.1.
The distributions of species-specific PCB 126 REP estimates are given as Tukey boxplots in Figure 3 . In order to remove the influence of redundant probe sets, the geometric mean REP was conservatively represented for each species using only the lowest Dp MLE (i.e., highest REP estimate) for each distinct gene expression measurement. The resulting geometric mean REPs were 0.0022 (95% CI ¼ 0.001, 0.005) and 0.057 (95% CI ¼ 0.03, 0.1) for human and rat genes, respectively. WilcoxonMann-Whitney tests on the Dp parameters found that the median human REP was significantly different from the median rat REP (p ¼ 1.6 3 10
À10
) and the median REP estimates from either species were significantly (p 0.05) less than 0.1. Figure 4 depicts the relationship between the estimated EC50s for TCDD and PCB 126 of all successfully modeled probe sets within each species. Redundant probe sets representing the same gene were included in Figure 4 in order to more accurately portray the full range of estimates obtained. The PCB 126 EC50 values were calculated by adding MLEs of model parameters p TCDD and Dp for each probe set. Clearly, the majority of EC50 PCB126 estimates for human probe sets are found at concentrations greater than À8 log 10 M, while most of rat probe sets had EC50 PCB126 estimates at concentrations less than À8 log 10 M. This aspect of the species differences in sensitivity to PCB 126 is not fully appreciated when just examining REPs since, as a ratio, it disguises the underlying EC50s.
Cross-Species Comparison of Modeled Genes
Successfully modeled genes were screened to identify rat/ human orthologs using the getHOMOLOG function of the R package annotationTools version 1.8.0 as described in detail in Supplementary File 1. Briefly, Entrez gene IDs prescribed to each probe set of interest were used to query the Homologene database for any associated orthologous genes for the opposing species. Forty-five distinct rat genes were identified as potential orthologs to the 47 modeled human genes. Human orthologs were identified for 62 out of 79 rat genes modeled. In this specific case, the failure to identify rat orthologs to two of the modeled human genes was due to microarray annotation error and 
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incomplete rat genome annotation. Although similar annotation problems resulted in a failure to identify human orthologs for some rat genes (e.g., UDP-glucuronosyltransferase isoforms), a number of modeled rat genes lack clear human orthologs (e.g., rat Mug1/2 and some cytochrome P450 isoforms). Only 24 of 45 identified human/rat orthologs modeled for human REP (i.e.,~53%) were represented by probe sets on the rat RG-U34A array. Yet, 57 of the 62 human/rat orthologs modeled for rat REP (i.e.,~92%) were represented by probe sets on the human HG-U133A array. Thus, orthologous probe sets for the vast majority of rat genes demonstrating doseresponse to TCDD and PCB 126 were also present on the human HG-U133A array yet failed to yield dose-response models. Conversely, many human modeled genes did not have a rat ortholog on the RG-U34A array. Wilcoxon-MannWhitney tests were performed, within each species, to detect significant differences between median REP estimates for orthologs shared across arrays versus those responsive genes that were not shared between the arrays. Differences (i.e., p 0.05) were not detected for either species using these tests, indicating that the clear species difference in REP estimates seen in Figure 3 is consistent regardless of whether the responsive orthologs were present on both species-specific arrays or not.
Only five orthologous genes (represented by 16 probe sets) were commonly modeled in both rat and human: rat Cyp1a1 (i.e., E00717UTR#1_s_at and E00778cds_s_at) and human CYP1A1 (i.e., 205749_at), rat Cyp1b1 (i.e., rc_AI176856_at and X83867cds_s_at) and human CYP1B1 (i.e., 202435_s_at, 202436_s_at, and 202437_s_at), rat Cyp1a2 (i.e., E01184cds_s_at and M26127_s_at) and human CYP1A2 (i.e., 207608_x_at and 207609_s_at), rat Nqo1 (i.e., J02679_s_at) and human NQO1 (i.e., 201468_s_at), and rat Hal (i.e., M58308_at) and human HAL (i.e., 206643_at). Interestingly, 
INTERSPECIES GENOMIC RESPONSE TO AHR AGONISTS
the HAL ortholog was induced in rat cells and repressed in human cells by both TCDD and PCB 126. The TCDD and PCB 126 dose-responses of each of the four orthologous genes induced in both species were modeled simultaneously to generate cross-species REP estimates (compared to rat TCDD) for human TCDD (i.e., rat TCDD EC50 divided by human TCDD EC50) and human PCB 126 (i.e., rat TCDD EC50 divided by human PCB 126 EC50). This crossspecies model also generated a rat TCDD EC50 and an ''intraspecies'' REP estimate for rat PCB 126 (i.e., rat TCDD EC50 divided by rat PCB 126 EC50). Complete methodology for cross-species REP modeling is given in the Cross-Species Dose-Response Modeling subsection of Supplementary File 1. Probe sets representing the HAL/Hal orthologs were not modeled for cross-species REP since the divergent direction of gene expression change between species would require a significantly more complex model. Table 5 displays the cross-species REP model parameter estimates for each of the modeled orthologous genes identified as induced in both species.
Gene Ontology and Kyoto Encyclopedia of Genes and
Genomes Enrichment Since few orthologs were found in common between species among the modeled genes, all modeled probe sets were screened for any enriched process or functional associations (i.e., gene ontology [GO] categories or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways) that may be shared between the two species. This could provide insight into the common genetic pathways of toxicity. The full methodology for GO and KEGG enrichment analysis is given in Gene Ontology and Pathway Analysis subsection of Supplementary File 1. Both induced and repressed probe set lists were analyzed together within each species, and either the RG-U34A or HG-U133A array served as the background for rat or human probe sets, respectively. Tables 6 and 7 summarize the terms significantly (p 0.05) enriched in human and rat probe set lists, respectively. Only three enriched terms were shared by both species: the GO molecular function term ''unspecified monooxygenase activity'' (GO:0050381) and KEGG pathways ''tryptophan metabolism'' (00380) and ''metabolism of xenobiotics by cytochrome P450'' (00980). Figure 4 demonstrates that in vitro-derived potencies and PCB 126 REPs vary somewhat across individual genes both within and between species. Variation in the mean TCDD EC50s among enriched categories was also seen for both species (Tables 6 and 7 ). The difference in the mean TCDD EC50 of the most and least sensitive category in either species was slightly greater than 10-fold. There was also variation in mean rat REP estimates across significantly enriched functional categories (Table 7) . For instance, the difference between mean REPs for the KEGG pathways ''arachidonic acid metabolism'' and ''caffeine metabolism'' is approximately 10-fold; yet, these two categories possess approximately the same TCDD EC50 (i.e., À10.9 log 10 M). Conversely, little variation was observed in mean PCB 126 REP estimates for enriched human pathways (Table 6) , with the possible exception of the slightly higher mean REP for the KEGG pathway ''bile acid biosynthesis'' which also possessed a comparatively higher mean TCDD EC50 (i.e., À8.9 log 10 M). Overall, data from the current in vitro study demonstrated that human REP estimates did not vary widely across significantly enriched gene functional categories. However, considerably more variation in REP for enriched categories was observed for rat data.
Incorporation of Chemical-Specific Dose-Response Models
In order to elucidate genes that were potentially responsive to either TCDD or PCB 126 in a chemical-specific manner and to capture important genes potentially missed when both chemicals were modeled simultaneously, models representing a single dose-response curve were attempted separately for each chemical (i.e., chemical-specific dose-responses). A similar model selection scheme to that depicted in Figure  1 was employed except that the initial fold change filter required a twofold change in at least two human subjects/rat pools for only the chemical of interest (i.e., the PCB 126 fold changed filtered probe set list differed from that used for REP modeling). Application of this modeling procedure using human probe sets generated additional models, not previously modeled for REP, for seven TCDD (i.e., one induced and six repressed) and 12 PCB 126 (i.e., 11 induced and 1 repressed) FIG. 4 . Relationship between the estimated EC50s for TCDD and PCB 126 for all successfully modeled probe sets. Note that more than one probe set in this figure may represent the same species-specific gene since redundant probe sets were included. The units for both axes are log 10 Molar. Symbols differentiate data for induced (triangles) and repressed (circles) dose-response genes. Four TCDD-only (i.e., one induced and three repressed) and 17 PCB 126-only (i.e., 4 induced and 13 repressed) models were also obtained for rat genes. Supplementary File 9 contains all output data for both human and rat probe sets successfully modeled for chemical-specific dose-responses. Figure 5 depicts the distribution of EC50s for TCDD and PCB 126 for all modeled rat and human genes including genes that responded in a chemical-specific manner. The probe set with the lowest EC50 was used to conservatively represent any redundant probe sets. Figure 5 clearly demonstrates that most human genes do not reach the EC50 level until the PCB 126 concentration exceeds À8 log 10 M, whereas the majority of rat genes reach their EC50 levels at TCDD and PCB 126 concentrations well below À8 log 10 M. Perhaps coincidently, the human TCDD response range appears to resemble the rat PCB 126 response range rather than that of rat TCDD. Except for the five orthologous genes, each treatment group represents different genes. Nevertheless, it is informative to note that, for those genes that did respond in a dose-dependent fashion, the treatments could be differentiated. The nonparametric Kruskal-Wallis rank sum test indicated significant differences (p ¼ 2.2 3 10 À16 ) among median EC50s of the experimental groups, and post hoc multiple comparison testing determined that the median rat EC50 for PCB 126 and human EC50s for TCDD and PCB 126 were significantly different (p 0.05) from the median rat EC50 for TCDD. Furthermore, the median EC50 PCB126 for human and rat were significantly different (p 0.05). Thus, this single chemical modeling procedure provided little additional evidence of divergent, chemical-specific genomic responses, in either species, as would be expected for these two full agonists of the AHR. (Drenth et al., 1998; Silkworth et al., 2005; Vamvakas et al., 1996; van Duursen et al., 2003; van Duursen et al., 2005; Westerink et al., 2008; Zeiger et al., 2001 ). This species difference in sensitivity is beyond the well-described approximately 10-fold species difference in AHR affinity for TCDD (Ema et al., 1994; Harper et al., 1988; Ramadoss and Perdew, 2004) . Competitive AHR-binding assays have indicated that the species difference in PCB 126 REP cannot be explained by species variation in PCB 126 relative affinity (i.e., compared to TCDD) for the AHR (Fan et al., 2009; Flaveny et al., 2009 ) and points toward a species discrepancy in PCB 126 relative intrinsic efficacy to activate the AHR. Since some toxicities attributed to TCDD and DLCs may be independent of the CYP1A1 enzyme (Nukaya et al., 2009; Pohjanvirta, 2009; Uno et al., 2004) , the present investigation utilized two species-specific microarrays, sharing over 4000 rat/human orthologs, to generate doseresponse models for genes responding to both TCDD and PCB 126. Thus, the goal of this study was to determine if the relative insensitivity of primary human hepatocyte cultures to PCB 126-induced CYP1A1 gene expression could be extended to other responsive genes.
The relatively large variation in the maximal agonist effect (i.e., a parameter) among human donors and even between rat pools for some, but not all, probe sets made modeling doseresponse quite challenging. However, the use of within-donor/ pool fold change values and the implementation of mixed-effects 268 models allowed for the generation of numerous dose-response models in either species. Despite this accomplishment, for many human probe sets, only two out of three donors displayed a robust dose-response while the third donor failed to respond >1.5-fold at any dose measured. This resulted in either a lack of model convergence or, if a model was generated, an extremely poor fit. Thus, implementation of the nonresponsive human donor removal procedure (step 2, Fig. 1 ) not only addressed the poorly fit models in an entirely automatic manner (i.e., not requiring additional visual inspection) but also allowed for the generation of 20 additional dose-response models. This additional procedure did add potential bias to this analysis toward finding more human dose-response genes; a bias not inconsistent with the major goal of this study.
It is tempting to speculate that the large variation in maximal agonist effect observed among the human donors/rat pools was due entirely to interindividual differences in susceptibility to TCDD and PCB 126 (i.e., biological variation) . Indeed, previous microarray investigations using primary human hepatocytes have observed large interindividual variations in both the basal expression hepatic enzymes (Slatter et al., 2006) and xenobiotic-induced gene expression (Goyak et al., 2008) . In addition, since the rat pools were made from tissue of entirely different outbred animals, there is no reason to believe that these cultures would result in identical maximal responses. However, due to several aspects of the experimental design used in the current study, owing primarily to the utilization of fresh human hepatocytes, such conclusions regarding maximal response cannot be definitively made. Although a single technical replicate did suggest that technical aspects following RNA isolation may not have greatly influenced the data, this did not rule out technical differences due to date of RNA isolation and cell culture among donors and between rat pools. However, incorporation of within-donor/pool fold change estimates and mixed-modeling procedures to account for individual-level variation did allow us to successfully model many genes displaying dose-response in this study. Because the goal of our study was to estimate PCB 126 REPs, the real source of maximal agonist effect variation was not of primary interest as long as it could be accurately modeled. Particularly, since the height of the right asymptote of any one doseresponse curve is not generally transferable across studies or end points, let alone species, making it more or less pharmacologically irrelevant in comparative studies.
The major goal of this study was to estimate species-specific PCB 126 REPs for all genes responding in a dose-response manner to both TCDD and PCB 126. The median PCB 126 REP estimate for 47 modeled human genes was significantly (p 0.05) lower than both the median REP estimate of 0.1 found in the Haws et al. (2006) database (derived mainly from rodent studies) and the median REP for the 79 rat genes modeled in the current study. This lower median human REP is in line with a previous human primary hepatocyte-derived REP estimate of 0.003 for ethoxyresorufin-O-deethylase (EROD) activity (Silkworth et al., 2005) . Importantly, Silkworth et al. (2005) utilized primary hepatocytes derived from five human donors, including all three human donors used in the present study. Several other investigations using human cells/cell lines have also demonstrated PCB 126 REP estimates well below 0.1 (Drenth et al., 1998; Pang et al., 1999; Vamvakas et al., 1996; van Duursen et al., 2003; Westerink et al., 2008; Zeiger et al., 2001) . The current genomic rat REP estimate was within an order of magnitude uncertainty of the Haws et al. (2006) median PCB 126 REP estimate of 0.1 and similar to previous REP estimates using rat primary hepatocyte EROD activity (Chen and Bunce, 2004; Silkworth et al., 2005; Zeiger et al., 2001) . Therefore, the relative insensitivity of primary human hepatocytes to PCB 126 could be extended to genes other than CYP1A1. Conversely, the relative ''sensitivity'' of primary rat hepatocyte cultures to PCB 126 also extends to genes other than Cyp1a1.
So, why do in vitro PCB 126 REP estimates vary between rat and human? Although recent studies have suggested that human and responsive rodent AHRs share approximately the same relative affinity (compared to TCDD) for PCB 126 (Fan et al., 2009; Flaveny et al., 2009) , there could conceivably be some aspect of initial receptor binding and occupancy related to species differences in PCB 126 REP that these studies have failed to quantitate. Perhaps, species differences in AHR structure affect some other aspect of receptor function downstream of initial ligand binding such as transactivation (e.g., Ramadoss and Perdew, 2005) or interaction with other signal transduction pathways. Finally, recent evidence of species differences in ligand-specific AHR-coactivator interactions (Zhang et al., 2008) might explain the relatively weaker PCB 126 REP in human cells.
Conceivably, the more relevant question to address is why PCB 126 is so potent in the rat. The median rodent-derived PCB 126 REP given in the Haws et al. (2006) database is within a half order of magnitude of median REPs for several polychlorinated dibenzodioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) (Haws et al., 2006 ); yet, PCB 126 has a much weaker affinity for the rat AHR than 2,3,7,8-tetrachloro dibenzofuran (TCDF) (~68-fold difference), 1,2,3,7,8-pentachloro dibenzodioxin (PeCDD) (~53-fold difference), and 2,3,4,7,8-pentachloro dibenzofuran (PeCDF) (~16-fold difference) (Fan et al., 2009) . Furthermore, the affinity of the human AHR for PCB 126 is at least 50-fold weaker than these same DLCs measured by Fan et al. (2009) , but in contrast to the rat, previous studies using human HepG2 cells expectedly estimate relatively higher REPs for 1,2,3,7,8-PeCDD (i.e.,~0.75; Lipp et al., 1992) and 2,3,7,8-TCDF (i.e.,~0.09; Wiebel et al., 1996) compared to PCB 126 (i.e.,~0.002; Silkworth et al., 2005) . All such data clearly demonstrate a peculiarly high intrinsic efficacy for PCB 126 to activate the rat AHR compared to human, over and above that expected for this class of ligand based solely upon receptor affinity.
A major finding of the current investigation was that the species-specific REP estimates generated for human and rat cell cultures were derived from relatively nonoverlapping sets of genes (i.e., only five orthologs were modeled in both species). Furthermore, only one GO category and two KEGG pathways were similarly enriched between species for TCDD/PCB 126 dose-response, complicating any attempt to translate REP estimates for most functional categories across species. Interestingly, Rowlands et al. (2007) found extremely limited gene overlap between rat and human primary hepatocytes (i.e., CYP1A1, CYP1A2, CYP1B1, TIPARP, and IL17RB) using microarrays following exposure to TCDD, TCDF, or 4-PeCDF. Common TCDD-responsive gene sets were also quite limited (<40 genes) in two in vivo comparative studies using more closely related rat and mouse strains (Boutros et al., 2008; Boverhof et al., 2006) . Since many of the toxic responses attributed to TCDD and DLCs appear to be shared between rat and mouse, these aforementioned in vivo rodent studies suggest a very limited repertoire of genes are directly involved in eliciting AHR agonist toxicity.
It is important to address the fact that most of the genes demonstrating dose-responses to both TCDD and PCB 126 in the present study were not shared between species. Failure to identify more commonly responsive human-rat orthologs may partly be technical in nature due to the incomplete overlap of genes represented on the two different microarrays, where only about half of the human genes modeled for REP had orthologs on the rat RG-U34A array. For instance, the well-described TCDD-responsive gene TIPARP (Ma et al., 2001 ) was modeled for human PCB 126 REP in the current study, but the rat Tiparp ortholog is not represented by the RG-U34A array. However, this technical issue does not address why human-derived dose-response models were not generated for 52 of the 57 orthologs modeled for rat REP that were also present on the human HG-U133A array. Furthermore, the two species-specific microarrays employed in the current study shared over 4000 rat/human orthologs; yet, only five orthologs were modeled for dose-response in both species. Previous cross-species genome-wide screens for phylogenetically and positionally conserved dioxin response elements (DREs) (Sun et al., 2004) and a preliminary gene promoter analysis of TCDD/PCB 126-responsive orthologs in the current study (data not shown) have clearly indicated that most core DRE sequences may not be well conserved between rat and human orthologs or even between rat and mouse orthologs. Furthermore, it appears that the human and rodent AHRs may differ greatly in their ability to recruit certain coactivator proteins (Flaveny et al., 2008; Zhang et al., 2008) . Species differences in coactivator recruitment are likely related to divergent AHR structure and might explain the discrepancy in genes responding in the present investigation. In addition, divergent AHR functioning may explain why approximately four times more induced genes than repressed genes were seen for human cells compared to a relatively even ratio of induced/repressed genes seen for the rat cultures of the present study and in previous in vivo rat studies (Boutros et al., 2008; Boverhof et al., 2006) . Although the exact mechanism for repression genes by TCDD is unknown, it appears that the AHR is required for the downregulation of at least some genes (Ovando et al., 2006) , and repression may involve AHR cross talk with other signal transduction pathways (Patel et al., 2009) .
One expectation of the current investigation, and of modern genomics in general, was that genes displaying clear doseresponses might be relatable to in vivo toxicities. Comparison of rat in vitro gene expression changes modeled in the current study with hepatic gene expression following acute exposure of rats to TCDD and Aroclor 1254 (Silkworth et al., 2008) has defined a set of in vivo-in vitro transferable rat genes including Cyp1a1, Cyp1a2, Cyp2a1/2, Cyp1b1, Cyp2b3, Nqo1, Ugt1a6, Ugt1a7, Igfbp1, Igf1, Mettl7b, and Tgfb1i4. Many of the same responsive rat genes identified in both the study of Silkworth et al. (2008) and the present study were also differentially expressed at 13 weeks of exposure of female SD rats to TCDD or PCB 126 (Vezina et al., 2004) and at 6-168 h following single oral gavage of male SD rats with TCDD (Fletcher et al., 2005) . Despite these aforementioned in vitro-in vivo similarities, a gene-by-gene comparison of the in vitro rat gene list obtained in the current study with the previously mentioned rat in vivo studies along with in vivo rat-mouse comparative studies by Boutros et al. (2008) and Boverhof et al. (2006) does reveal that many responses observed in the rat liver in vivo may not be predicted by in vitro responses. Differences in gene lists between in vivo-in vitro studies most likely involve a multitude of factors. For instance, Dere et al. (2006) compared in vivo-in vitro genomic responses to TCDD in mouse liver/mouse hepatoma cells and found exposure system differences that may have been either artifacts of cell culture (i.e., cell cycle genes) or secondary in vivo responses previously found to be well downstream of primary AHR signaling (Hayes et al., 2007) . Also, in some cases, the comparability of the present in vitro study with these in vivo investigations is limited due to the use of different animal strains, genders, and array platforms. Overall, one cannot expect primary cultures of a single cell type (e.g., hepatocytes) to entirely mimic the in vivo response of a complex organ such as the liver. Clearly, more information is needed to determine which gene expression changes observed in these previous in vivo studies demonstrate robust dose-responses and are related to actual toxic events. Nonetheless, the initial events eliciting in vivo toxicity of TCDD and DLCs most likely involves AHR activation of gene expression. Therefore, at least some of the potency and REP estimates made in the current in vitro study, which were entirely consistent with AHR regulation, will likely be relevant to AHR-mediated toxicity in vivo.
Mechanistic studies in various animal models, ranging from fish to birds and rodents, have determined that TCDD toxicity is mediated by the AHR. Although the genes modeled for rats and humans in this study were generally not the same, both sets were consistent with AHR regulation, that is, they responded in a dose-response manner to both TCDD and PCB 126. 270 Therefore, the REP estimates for these genes may be relevant to potential TCDD and PCB 126 hepatotoxicity in humans. Although the liver is perhaps the most sensitive target organ in the rat to TCDD and DLC toxicity, evidence in highly exposed humans suggests that human liver might not be a sensitive target organ for AHR-mediated toxicity. Since the skin is clearly the most overtly responsive human target organ to TCDD and DLC toxicity, future studies in our laboratory will focus on determining in vitro REPs for the most toxic DLCs in rodents (i.e., PCB 126, PCDDs, and PCDFs) using normal human epidermal keratinocytes.
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